Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $1.708 million which beat the analyst consensus estimate of $925.000 thousand by 84.65 percent.